We characterized the two species of lipoproteins containing apolipoprotein A
L ecithin: cholesterol acyltransferase (LCAT, EC 2.3.1.4.3) catalyzes esterification of plasma cholesterol. 1 In plasma, LCAT is associated with high-density lipoprotein (HDL) and esterifies free cholesterol (FC) on HDL, 24 The cholesteryl esters (CEs) generated on HDL are transferred to other lipoproteins by cholesteryl ester transfer protein (CETP), '-7 and most of the CEs in plasma are generated by the action of LCAT. 8 Thus, a deficiency of this enzyme results in severe structural and compositional changes in all lipoproteins. The HDL of patients with LCAT deficiency differs from that of normal subjects and has been found to consist of two populations of HDL: one of high molecular weight (HMW-HDL) and the other of relatively low molecular weight (LMW-HDL).
911 HMW-HDL contains discshaped HDL particles, whereas LMW-HDL contains very small spherical HDL particles. 11 All of these lipoproteins have a higher ratio of lipid to protein, thereby suggesting that the HDL of patients has a lower density than that of normal subjects. 10 In addition, a considerable amount of plasma apolipoprotein A-I (apoA-I) is found in the lipoprotein-free fraction (d>1.21 g/mL fraction). 12 Al-though apoA-I in the d>1.2\ g/mL fraction has yet to be characterized, it is thought to be dissociated from HDL during ultracentrifugation. Because ultracentrifugation affects the composition and structure of lipoproteins, some previous reports on lipoproteins in LCAT deficiency may have reflected some artifacts due to ultracentrifugation. ApoA-I-containing lipoproteins isolated by immunologic methods probably better reflect the native state of these particles than does the HDL isolated by ultracentrifugation. 1315 These lipoproteins consist of two subspecies: one contains apoA-I but no apoA-II (LpA-I), and the other is a lipoprotein containing both apoA-I and apoA-II (LpA-I/A-II). As reported by Cheung et al 4 and Marcel et al, 16 most plasma LCAT and CETP are associated with LpA-I in normal subjects. Furthermore, some of these lipoproteins are created during liporysis of chylomicrons and very-low-density lipoproteins (VLDLs). 17 In LCAT deficiency, catabolism of chylomicrons and VLDLs is altered. 18 ' 19 Thus, in LCAT deficiency, chylomicrons, VLDLs, and their remnants may include apoA-I-containing lipoproteins, ie, precursors of LpA-I or LpA-I/A-II. In the present study, as a first step to further clarify the role of LCAT in lipoprotein metabolism, we characterized the physicochemical nature of LpA-I and LpA-I/A-II in four homozygotes for LCAT deficiency.
Methods

Subjects and Materials
We studied four homozygotes (patients 1, 2, 3, and 4) for familial LCAT deficiency. Patient 3 and patient 4 were relatives, but the others were not. Chemical features and laboratory findings in these subjects have been reported elsewhere.
LCAT mass and activity of the normal control subjects. Patient 1 was on a vegetarian diet with a low calorie intake (1900 kcal/d) and a restricted fat consumption (25 g fat/d). Patient 1 was apparently healthy and was not taking any medication that might affect lipoprotein metabolism. Patients 2 and 3 were in chronic renal failure. Patient 2 was treated with hemodialysis and patient 3 by a kidney transplant (currently failing). Patient 4 has anemia but no renal involvement. EDTA-anticoagulated blood samples were obtained from all subjects after an overnight fast. Samples from patients 3 and 4 were shipped the same day, on ice, from Vancouver, Canada, to Japan. Control samples for comparison were obtained from the plasma of 40 normolipidemic subjects (20 men and 20 women, aged 25 to 45 years) who were not taking any medication. All chemicals used were of the highest grade available from commercial sources. H]cholesterol (21.9 Ci/mmol) was purchased from Du Pont-New England Nuclear.
Isolation of LpA-I and LpA-I/A-II From Plasma
LpA-I and LpA-I/A-II were isolated from each plasma sample from patients and control subjects by a combination of anti-apoA-I and anti-apoA-II immunosorbent columns, as described elsewhere. 15 -23 Briefly, plasma was applied on an anti-apoA-I column. After extensive washing with 0.01 mol/L tris(hydroxymethyl)aminomethane (Tris), 0.5 mol/L NaCl, and 1 mmol/L EDTA, pH 7.5 (buffer A), the column was eluted with 0.1 mol/L acetic acid and 1 mmol/L EDTA, pH 3.0. Each effluent was immediately adjusted to pH 7.4 with 1.0 mol/L Tris solution and dialyzed against 0.15 mol/L NaCl and 1 mmol/L EDTA, pH 7.4 (buffer B). Finally, the sample was concentrated in buffer B using an ultrafiltration cell (Amicon Corp) equipped with a PM-10 membrane and then applied on an anti-apoA-II column. The column was washed with buffer A to obtain LpA-I. The bound fraction was eluted from the column to obtain LpA-I/A-II. Both LpA-I and LpA-I/A-II were dialyzed and concentrated in buffer B. In this procedure, more than 90% of lipids and apolipoproteins were recovered in the unbound and bound fractions. When the plasma fraction not bound to the anti-apoA-I column was applied to an anti-apoA-II column, no bound fraction was obtained for the homozygous patients. Thus, we considered that all plasma apoA-JJ in the homozygotes was associated with apoA-I, ie, as LpA-I/A-II. 
Assay for Cholesterol Esterification in
Incubation of LCAT-Deficient Plasma With LCAT
Combined plasma from patient 3 and patient 4 was incubated with lipoprotein-deficient plasma (LCAT source) at 37°C for 16 hours. Lipoprotein-deficient plasma (LDP) was isolated from fresh plasma by the methods of Barter et al. 24 The supernatant recovered after ultracentrifugation at 150 OOOg for 48 hours at a density of 1.25 g/mL was subjected to a second 48-hour spin at d=l.25 g/mL. The upper one third of the infranatant after the second spin was recovered and added to the first 1.25-g/mL infranatant. LDP was concentrated twofold and dialyzed against PBS. Combined plasma (6 mL) from patient 3 and patient 4 was incubated with 3.0 mL LDP. After incubation, LpA-I and LpA-I/A-II were isolated from the incubation sample, as mentioned above.
Electron Microscopy
Small aliquots of lipoproteins were mixed with an equal volume of 2% sodium phosphotungstate, pH 7.4, and a droplet was placed on a Formvar/carbon-coated grid. Excess fluid was removed from the grid with filter paper, and the negatively stained preparation was immediately examined in a JEOL JEM-2000EX microscope. Photomicrographs were taken at an instrument magnification of x60 000, and the final magnification of electron photomicrographs was x 150 000.
Electrophoretic Analysis
Agarose gel electrophoresis was performed using a Pol-E film system for lipoproteins (Chiba Corning). Lipoproteins were stained with fat red 7B for lipid staining and Coomassie brilliant blue R for protein staining. Staining for protein and lipid was carried out on the same gels. The apparent hydrated particle diameter of LpA-I and LpA-I/A-II was estimated by gradient polyacrylamide gel electrophoresis (GGE) on Pharmacia precast PAA 4/30 gels, according to the procedure specified by the manufacturer. Electrophoresis calibration kits for HMW or LMW proteins (Pharmacia) were used. The stained gels were scanned with a laser densitometer (Shimadzu, model CS-9000). The area under the curve for each particle was calculated by integration. The Stokes' diameters of these HMW proteins are (in nanometers): thyroglobulin 17.0, apoferritin 12.2, catalase 10.4, lactate dehydrogenase 8.2, and bovine albumin 7.5.
Protein and Lipid Analysis
The apoA-I, apoA-II, and apoE concentrations in plasma, LpA-I, and LpA-I/A-II were measured by radial immunodiffusion assay. 25 - 26 Total cholesterol (TC), FC, triglyceride, and phospholipid concentrations of these samples were determined by enzymatic methods using commercial kits. CE was calculated by subtracting FC from TC, as measured by enzymatic methods. HDL cholesterol (HDL-C) was measured by selective precipitation of low-density lipoprotein using phosphotungstate/MgC^. 27 - 28 The protein content of each fraction from the immunosorbent columns was determined by the method of Lowry et al. 29 Values of lipids and apolipoproteins in LpA-I and LpA-I/A-II were corrected based on the percent recoveries during isolation.
Results
Endogenous Cholesterol Esterification by LpA-I and LpA-I/A-U
We determined the esterifying capacity for FC of LpA-I and LpA-I/A-II in the homozygotes. As shown in Table 1 , these lipoproteins in patient 3 and patient 4 did not esterify FC, whereas those in patient 2 and patient 1 did esterify a small amount of FC. These results are consistent with their residual plasma LCAT mass and activity values LpA-l indicates lipoproteins containing only apolipoprotein A-l; LpA-l/A-ll, lipoproteins containing apolipoproteins A-l and A-ll; and LCAT, lecithin:cholesterol acyttransferase. In patients 3 and 4 LCAT mass and activity were negligible. In patients 1 and 2, LCAT mass and activity were 5% to 15% of normal control subjects. Percentages were calculated on the basis of esterification of pHJfree cholesterol in LpA-l or LpA-l/A-ll. Mass is expressed as nanomoles per 16 hours per 200 /ig protein.
*Mean±SD of 10 normolipidemic subjects (5 males and 5 females).
reported elsewhere. 1922 In the following study, we divided homozygotes into two groups based on residual LCAT activity. The two Canadian homozygotes (patient 3 and patient 4) apparently have no LCAT mass and activity, whereas the two Japanese patients (patient 1 and patient 2) have a small amount of LCAT mass and activity (5% to 15% of normal control subjects).
Plasma Lipid and Apolipoprotein Concentrations in Patients With LCAT Deficiency
All four patients had low concentrations of CE, HDL-C, apoA-I, and apoA-II and increased concentrations of trigryceride and apoE when compared with control subjects (Table 2) . With respect to FC and phospholipids, patient 1 showed lower and other homozygotes showed higher concentrations, respectively. The ratio of CE to FC in all homozygotes was lower than that of control subjects (patient 3, 0.14; patient 4, 0.07; patient 2, 0.35; patient 4, 0.29; control subjects, 2.56). Serum HDL-C, apoA-I, and apoA-II levels and the ratio of CE to FC were lower in patients 3 and 4 than in patients 1 and 2.
Chemical Composition of LpA-I and LpA-I/A-II in LCAT Deficiency
LpA-I
As shown in Table 3 , the absolute concentrations of CE, phospholipids, and apoA-I in LpA-I of all homozygotes were dramatically lower than those of control subjects. FC and trigryceride concentrations were decreased only in patients 1 and 2. ApoE concentrations were similar to those in control subjects. In normal subjects, 41% of plasma apoA-I was located in LpA-I; however, in the four patients, the majority of plasma apoA-I resided in LpA-I (patients 3 and 4, average 73%; patients 1 and 2, average 64%). To clarify whether these findings were due to quantitative or qualitative changes in LpA-I particles, we determined the percent lipid and protein composition of LpA-I (Table 4) . Patients 3 and 4 had higher percentage of FC and lower percentage of CE, whereas patients 1 and 2 showed a higher percentage of protein and a lower percentage of CE and of triglyceride, than did control subjects. When patients 3 and 4 were compared with patients 1 and 2, percentage of protein and percentage of CE was lower and percentage of FC and triglyceride higher in patients 3 and 4 than in patients 1 and 2. The proportion of core (CE+triglyceride) to surface (FC+phos-pholipids) lipid was significantly decreased in all four. These data indicate that there were both qualitative and quantitative changes in the patients' LpA-I.
LpA-I/A-II
As shown in Table 3 , all lipids except FC and all apolipoprotein concentrations in LpA-I/A-II were markedly lower in all homozygotes as compared with the respective findings in control subjects. To clarify whether these changes were due to quantitative or qualitative changes in LpA-I/A-II particles, we determined the percentage of lipid and protein composition of LpA-I/A-II (Table 4 ). In patients 3 and 4, compositional differences were found in all components except triglyceride. Relative composition showed that FC and phospholipids were increased and that protein and CE were decreased. In patients 1 and 2, the proportion of CE was slightly lower than that in control subjects. The proportion of core to surface lipid was decreased in both groups but was more marked in patients 3 and 4. See the footnote to Table 2 for details.
Total lipid mass ratios of LpA-I to LpA-I/A-II in all four homozygotes were 0.9 to 1.4 (control, 0.7±0.1; mean±SD). Total protein mass ratios of LpA-I to LpA-I/A-n in both groups were 1.2 to 2.0 (control, 0.5±0.1). These data indicate that, differing from the normal (LpA-I/A-II being the dominant particle population 15 ), LpA-I is the dominant species of apoA-I-containing Iipoproteins in homozygotes. To obtain further information on LpA-I and LpA-I/A-II in homozygotes, we analyzed these Iipoproteins by electron microscopy.
Characterization of LpA-I and LpA-I/A-II by Electron Microscopy
LpA-I
Electron photomicrographs of negatively stained LpA-I are shown in Fig 1. Normal LpA-I contained spherical particles of 6 to 50 nm diameter. Predominant particles were small and spherical, 6 to 12 nm in diameter (Fig 1C) . LpA-I in patients 3 and 4 consisted of disc-shaped particles, 15 to 40 nm in diameter and 5 nm thick, and spherical particles, 6 to 40 nm in diameter (Fig 1A) . Most disc-shaped particles were 18 to 25 nm in diameter, and predominant spherical particles were 6 to 10 nm in diameter. Most of the LpA-I particles from patients 1 and 2 were spherical, of 6 to 30 nm in diameter, with a predominance of particles of 6 to 10 nm (Fig IB) . A disc-shaped particle is not evident in Fig  IB, but a small number of disc-shaped particles were seen in other electron photomicrographs (not shown). Fig 2 shows electron photomicrographs of negatively stained LpA-I/A-II. Normal LpA-I/A-II contained spherical particles of 8 to 60 nm in diameter, and the predominant particles were 8 to 10 nm in diameter ( Fig  2C) . As shown in Fig 2A and 2B , most of the LpA-I/A-II particles in all patients were spherical. However, differing from the norm, large spherical particles of 60 to 100 nm in diameter were observed in all patients. In patients 3 and 4, the predominant particles were 10 to 20 nm in diameter but in patients 1 and 2, particles 8 to 10 
LpA-I/A-II
Characterization of LpA-I and LpA-I/A-II by Gradient Gel Electrophoresis
When LpA-I and LpA-I/A-II particles were separated by nondenaturing GGE, different particle size distributions were evident (Fig 3) . The relative concentrations of these particles were determined by densitometry of GGE gels (Table 5) .
LpA-I
Normal LpA-I migrated as two distinct particles (11.1 nm and 8.8 nm in diameter; Fig 3, N) . A few particles 25 nm in diameter were also detected. However, as shown in Fig 3, LpA-I in LCAT deficiency showed different profiles. Small particles (7.7 nm in diameter) were predominant in all patients. A considerable number of large particles 12 to 25 nm in diameter were also present in all patients. However, these large particles were less evident in patients 1 and 2 than in patients 3 and 4. Particles 12.0 nm in diameter were not detected in patients 1 and 2. Disc-shaped particles did not migrate on GGE to the same position as did spherical particles of equal diameter but instead migrated to a position approximating that of spherical particles with a calculated diameter of [ (1.5 <ft) w , where d and t are disc diameter and thickness, respectively]. 30 On the basis of the diameter and thickness of disc-shaped particles, most disc-shaped particles (18 to 25 nm in diameter) might migrate to a position indicative of particles 13.4 to 16.7 nm in diameter. Therefore, it is suggested that 12-to-25-nm particles contain some that are discshaped. Twenty-one percent to 23% of LpA-I in patients 1 and 2 were 11.1-nm particles, but in patients 3 and 4 the 11.1-nm particles accounted for less than 1%. Particles of 8.8 nm in diameter were few in all four patients.
LpA-I/A-II
On GGE, the majority of LpA-I/A-II particles in patients 1 and 2 had a size similar to those from normal control subjects (8 to 10 nm in diameter; Fig 3) . However, LpA-I/A-II from patients 3 and 4 migrated as large particles 12 to 17 nm in diameter; most of these were spherical (Fig 2A and 2B) .
Characterization of LpA-I and LpA-I/A-II by Agarose Gel Electrophoresis
Because very large particles (>25 nm in diameter) do not enter the gradient gel, agarose electrophoresis was used for their characterization.
LpA-I
As shown in Fig 4A and Table 6 , 95% of normal LpA-I migrated as a broad band in the a r a 2 region, and a very faint band was detected in the /3 region. LpA-I in LCAT deficiency showed different patterns. In patients 3 and 4, 59% to 63% of LpA-I migrated in the p region and 37% to 41% was detected in the a r a 2 region. In patients 1 and 2, 33% to 38% of LpA-I migrated in the P region, and 62% to 67% was found in the a r a 2 region. When stained for protein (Fig 4B and Table 6 ), normal LpA-I yielded two bands: 73% in the a t region and 24% in the a 2 region. A faint band was visible in the p region. Protein distribution on the agarose gel was also different from that seen in normal control subjects. However, unlike the situation with lipid staining, LpA-I from patients 3 and 4 and patients 1 and 2 showed similar protein bands: 49% to 56% in the a 2 region and 17% to 23% in the a, region, with lesser amounts in the p region (25% to 30%). These data suggest that LpA-I from patients 3 and 4 contains larger and more lipidrich particles with /3-mobility than those from patients 1 and 2. On the basis of GGE patterns, particles of 7.7-nm diameter appeared to migrate in the a 2 region with little overlap with the a x region.
LpA-I/A-II
As shown in Fig 4A and 4B , unlike the situation with LpA-I, lipid and protein staining for LpA-I/A-II showed similar patterns. With lipid staining, most normal LpA-I/A-II migrated in the a r a 2 region, and a very faint band was also detected in the fi region. In patients 3 and 4, most LpA-I/A-II migrated in the a 2 region, and a small amount of ^-migrating LpA-I/A-II was detected. LpA-I/A-II from patients 1 and 2 showed a pattern similar to that from control subjects but with a few morê -migrating particles. Patterns similar to those of lipid staining were observed with protein staining, but no band in the /3 region was detected for any subject. These data suggest that ^-migrating LpA-I/A-II particles are lipid rich and protein poor.
Characterization of LpA-I and LpA-I/A-II After Incubation of LCAT-Deficient Plasma With LCAT
To determine the effect of LCAT on LpA-I and LpA-I/A-II in homozygotes, we incubated combined plasma from patient 3 and patient 4 with LCAT and characterized these lipoproteins.
LpA-I
After incubation with LCAT, isolated LpA-I consisted of three distinct particles: 10.2% of 11.1 nm, 61.6% of 8.8 nm, and 28.2% of 7.5 to 8.0 nm. Large particles > 12 nm in diameter were not evident. The weight ratios of protein, FC, CE, TG, and PL in LpA-I was 84.0:2.2:1.1:5.0:7.7. When compared with the original LpA-I from patients 3 and 4 (Table 4), the proportion of protein and CE was increased and that of FC and PL decreased after incubation with LCAT. Similar differences in protein and lipid composition were also found between patients 3 and 4 and patients 1 and 2 (Table 4) , thereby suggesting that residual LCAT activity in patients 1 and 2 was responsible for these differences.
LpA-I/A-II
After incubation of LCAT with the combined plasma of patient 3 and patient 4, the weight ratio of protein, FC, CE, TG, and PL in LpA-I/A-II was 63.1:1.8:7.1:5.4:22.6, and the particle size of isolated LpA-I/A-II was similar to that of normal control subjects. Large particles (12 to 17 nm) were never observed.
Discussion
We obtained evidence that (1) two thirds of apoA-Icontaining lipoproteins in homozygotes for LCAT deficiency are LpA-I, (2) LpA-I particles consist of both disc-shaped and spherical particles, although >50% of LpA-I are spherical particles 7.7 nm in diameter, (3) LpA-I/A-II particles in homozygotes contain spherical particles 8 to 17 nm in diameter and very large spherical particles 60 to 100 nm in diameter, and (4) LCAT promotes maturation of disc-shaped and spherical particles >12 nm in diameter of LpA-I and LpA-I/A-II more efficiently than 7.7-nm spherical particles.
In the present studies, for the first time all apoA-Icontaining lipoproteins were isolated from the plasma of LCAT-deficient homozygotes. Small particles (7.7-nm diameter) were found only in LpA-I. In a previous report, these particles were thought to be rich in apoA-I. 31 Our observations extend those of Torsvik, 31 in that apoA-II was not present in these particles. Most disc-shaped particles are currently thought to contain both apoA-I and apoA-II. 30 - 31 LpA-I and LpA-I/A-II particles in LCAT-deficient homozygotes also contain disc-shaped particles; however, many more disc-shaped particles were seen in LpA-I (Figs 1 and 2 ). This finding indicates that most disc-shaped particles in homozygotes are LpA-I. Mitchell et al 30 reported apoE-rich disc-shaped particles in homozygotes that contained more apoE than apoA-I. However, as shown in Table 3 , our LpA-I and LpA-I/A-II contained more apoA-I than apoE, similar to findings in normal control subjects. Thus, we concluded that most apoE-rich disc-shaped particles might not be apoA-I-containing lipoproteins. Studies with HepG2 cells have shown that they secrete large, spherical LpA-I/A-II particles 9.2 to 17 nm in diameter. 32 The size of these particles is close to our large LpA-I/A-II particles (12 to 17 nm). In addition, most plasma apoA-II is secreted from the liver. 33 All these results suggest that the large LpA-I/A-II particles (12 to 17 nm) found in homozygotes are nascent LpA-I/ A-II. With respect to the very large, spherical LpA-I/ A-II particles (60 to 100 nm in diameter), no such particle has been previously noted in HDL fractions and HepG2-secreted LpA-I/A-II.
11 -3032 However, Forte et al 11 found similarly sized particles in LDL fractions in LCAT-deficient homozygotes. Although LDL was not analyzed in the present study, it seems likely that the abnormally large LDL particles contain large LpA-I/ A-II particles. Further studies are needed to characterize these very large particles.
The differences in apoA-I-containing lipoproteins between patients 3 and 4 and patients 1 and 2 provide several new insights into the role of LCAT and the maturation of LpA-I and LpA-I/A-II. For LpA-I, discshaped and 12-to-17-nm particles were fewer in patients 1 and 2 compared with patients 3 and 4. In contrast, the (Table 5 ). These results suggest that (1) >12-nm LpA-I particles are precursors of 11.1-nm LpA-I particles, (2) a small amount of residual LCAT activity in patients 1 and 2 plays an important role in the maturation of these particles, and (3) precursors of 8.8-nm LpA-I particles differ from those of 11.1-nm LpA-I particles. To gain support for these notions, we incubated plasma from patients 3 and 4 with LDP, an LCAT source. After incubation, particles >12-nm diameter disappeared and the number of 7.7-nm particles was reduced. Seventy-two percent of LpA-I particles were of normal size. However, differing from normal were the dominant 8.8-nm particles (10.2%, 11.1 nm and 61.6%, 8.8 nm). These data clearly show that LCAT reacted to >12-nm and 7.7-nm LpA-I particles, and as a result, 11.1-nm and 8.8-nm LpA-I particles were created. The LCAT in LDP or the availability of FC during incubation may be inadequate to complete the maturation of all 7.7-nm particles. When comparing these results with the findings in patients 1 and 2 (Table 5) , the proportion of 8.8-nm particles was much lower than that of LpA-I isolated after incubation. However, the proportion of 11.1-nm particles in patients 1 and 2 was higher than that of LpA-I after incubation. This means that for maturation of the precursors of 8.8-nm particles, more LCAT activity than that in the plasma of patients 1 and 2 was needed, and 8.8-nm particles are not precursors of 11.1-nm particles. In this regard Marcel et al 16 reported that most CETP is associated with 8.8-nm LpA-I particles. Although CET activity in our LCAT-deficient patients was slightly lower than that in control subjects, 21 it seems likely that the precursors of 8.8-nm particles in homozygotes may acquire CETP during maturation, and if so, the residual LCAT activity in patients 1 and 2 would be insufficient to promote the maturation of precursor particles because of quick transfer of newly formed CE to other lipoproteins. Considering the fact that particles >12 nm represent 40% to 50% of LpA-I (Table 5 , patients 3 and 4), all of these results suggest that LpA-I particles >12 nm contain precursors of both 11.1-and 8.8-nm particles and most 7.7-nm particles are precursors of only the 8.8-nm LpA-I particles. Because 11.1-nm LpA-I particles were recovered in HDL 2 fractions and 8.8-nm particles in HDL3 fractions by ultracentrifugation (unpublished observation), the aforementioned suggestion is consistent with the report of Norum et al 34 that large, disc-shaped HDL is converted to HDL 2 and very small, spherical HDL is converted to HDL3 by incubation with LCAT. In the case of LpA-I/A-II after incubation with LCAT, large particles were converted to normal-size LpA-I/A-II particles. Thus, we suspect that large LpA-I/ A-II particles are precursors of normal LpA-I/A-II. In addition, the particle size of LpA-I/A-II in patients 1 and 2 was similar to that of normal control subjects. Taken together, these data suggest that LCAT promotes maturation of LpA-I/A-II more efficiently than that of LpA-I. All of our data emphasize the importance of LCAT in modifying the chemical composition, size, and shape of apoA-I-containing lipoproteins.
